Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$7.18 USD
+0.04 (0.56%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $7.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Mesoblast Limited [MESO]
Reports for Purchase
Showing records 41 - 60 ( 91 total )
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
High Confidence in Ryoncil Approval; Multiple Upcoming Catalyts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Raising Price Target to $20.00 (from $15.00) as Remestemcel Receives Positive ODAC Vote in SR-aGVHD
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Positive ODAC Vote Paves Way For Ryoncil Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
We Remain Bullish on Ryoncil Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Two Milestones Ahead - Steroid Refractory GvHD Advisory Panel Ahead - COVID ARDS Interim Analysis
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
COVID-19 ARDS Phase III readout later this year
Provider: Edison Investment Research Limited
Analyst: JACOBS M
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
COVID-19 Associated ARDS; A Near-term Catalyst; Higher $21 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Steady Progress on Three Pivotal Fronts
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: RYONCIL More Data Published, Be Sureto Tune-In to Tomorrow?s Update Call After the Close
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: The Phase 2/3 ARDS COVID19 First Patient Enrolled
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY-The Phase 2/3 ARDS COVID19 Trial Plans Announced
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Promising First Peek at Remestemcel-L for COVID-19 Associated ARDS; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Takeaways From Virtual Fireside Chat on COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Evidence Continues to Build for REMESTEMCEL?s Efficacy in Lung Disease Suggesting a COVID-ARDS Treatment
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Ryoncil to Enter Clinic for COVID-19 Associated ARDS; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
REMESTEMCEL COVID-19 ARDS - Clearance Granted
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Ryoncil Potential Approval by September 30; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S